A Phase II Randomized Placebo-Controlled Study Investigating the Combination of Yiv-906 and Sorafenib (SORA) in HBV (+) Patients (pts) with Advanced Hepatocellular Carcinoma (HCC)
JOURNAL OF CLINICAL ONCOLOGY（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要